Thomas E Mürdter

7PUBLICATIONS
36CO-AUTHORS
BiomaterialsSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 11, 2026
The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors.

|Dec 11, 2025
Feasibility of Patient-Derived 3D Gastrointestinal Stromal Tumour Models as Alternatives for In Vivo Mouse Models.

Dina Mönch, Julia Thiel, Meng Dong

|Oct 02, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial.

Thomas E Mürdter, Werner Schroth, Matthew P Goetz

|Feb 06, 2025
Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer.

Werner Schroth, Thomas E Mürdter, Matthias Schwab

|Mar 05, 2022
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer.

Alexander Rau, Nicole Janssen, Lennart Kühl

|May 30, 2020
Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models.

Corinna J Mohr, Werner Schroth, Thomas E Mürdter

Pageof 2

Frequent Collaborators

5 joint publications

Matthias Schwab

2 joint publications

Lennart Kühl

2 joint publications

Katrin S Kurz

2 joint publications

Monilola A Olayioye